DasiDiem (dapagliflozin/sitagliptin)
/ Dong Wha
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 13, 2025
KLIMT: DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes
(clinicaltrials.gov)
- P4 | N=196 | Recruiting | Sponsor: Dong Wha Pharmaceutical Co. Ltd.
New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
1 to 1
Of
1
Go to page
1